Our paper titled “Structure-based design and classifications of small molecules regulating the circadian rhythm period” is published in Scientific Reports. This work is done with collaboration wit Prof Metin Türkay.
Our review paper is published in Current Opinion in Chemical Engineering. The review highlights recent development in drug discovery against core clock proteins.
Serefs’ preprint paper is published on BioRxiv. This paper is entitled “Discovery of a small molecule that selectively destabilizes Cryptochrome 1 and enhances life span in p53 knockout mice” and describes discovery of a molecule, M47, selectively reduces half- life of mammalian Cryptochrome 1.
M47 enhanced the effect of oxaliplatin in p53 null mouse skin fibroblast (MSF) cells.
(A) Ras pT24 transformed p53 null MEF fibroblast cells were treated with 0, 10 or 20µM oxaliplatin and incubated for 24h. Then either DMSO or M47 was added and incubated for 16h. Cells were lysed and analyzed via protein immunoblot technique. At each cases M47 increases the cleaved PARP protein level and decreases CRY1 levels. Bar graph was drawn normalizing to 10µM dosage of oxaliplatin (Data represent the mean ± SEM, n=4 **: p < 0.005, versus DMSO control by two-way ANOVA). (B) M47 in p53−/−mice reduces age adjusted tumor incidence. Kaplan–Meier survival analysis (log-rank test) of the time of death with evidence of tumors showed significant differences between vehicle treated p53−/− and M47 treated p53−/− (**p<0,01)
Şeref’s paper titled “The Arg293 of Cryptochrome 1 is responsible for the allosteric regulation of CLOCK-CRY1 binding in circadian rhythm” is accepted to be published in Journal of Biological Chemistry.
Şeref’s paper titled “In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials” is accepted to be published in Journal of Biomolecular Structure and Dynamics.
The paper describes identification of well-tolerated and widely used drugs that have potential to be used against SARS-CoV-2
Our collaborative paper titled “Human CRY1 variants associate with attention deficit/hyperactivity disorder” where we functionally characterized CRY1-Delta6 is published in The Journal of Clinical Investigation.
Sibel’s paper titled “CRY1-CBS binding regulates circadian clock function and metabolism” is accepted to be published in The FEBS Journal.
This paper provide a novel insight that CBS-CRY1 binding provides a post-translational switch to modulate cellular circadian physiology and metabolic control.
Yağmur and Darya’s paper titled “A CLOCK-binding small molecule disrupts the interaction between CLOCK and BMAL1 and enhances circadian rhythm amplitude” is published in Journal of Biological Chemistry. 295(11):3518-3531
This paper describe the discovery of the small molecules has potential to be used as drug to eliminate circadian clock related diseases in ageing.
Our laboratory is interested in understanding how clock works at cellular level. For more information please visit our research interest section.